[8-K] Silexion Therapeutics Corp Reports Material Event

Rhea-AI Filing Summary

Silexion Therapeutics Corp (NASDAQ: SLXN) filed a Form 8-K on 9 July 2025 under Item 7.01 (Regulation FD). The sole purpose of the filing is to furnish — not file — a press release (Exhibit 99.1) titled “Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines.” No additional financial statements or transaction details are included, and the company explicitly states the information is not incorporated by reference into other Securities Act filings.

Key points

• The press release reports positive preclinical efficacy for SIL204 in human lung cancer cell lines.
• The disclosure is furnished under Regulation FD, ensuring simultaneous public access to the information.
• No revenue, cost, guidance, or clinical-stage data accompany the announcement.
• Exhibits attached: 99.1 (press release) and 104 (Inline XBRL cover data).

Investors receive confirmation of encouraging scientific data but must consult Exhibit 99.1 for experimental specifics, as the 8-K itself contains minimal detail.

Positive

• Encouraging preclinical efficacy for lead candidate SIL204 in human lung cancer cell lines, potentially advancing the drug development pipeline.
• Regulation FD disclosure ensures broad, simultaneous investor access, reinforcing transparency.

Negative

• None.

Insights

Biotech Analyst

TL;DR: Positive preclinical signal for SIL204; early but directionally favorable for SLXN.

Because oncology assets often see valuation inflections at preclinical milestones, the disclosure of "significant efficacy" in human lung cancer cell lines is incrementally positive. However, the 8-K lacks quantitative metrics (e.g., IC50, tumor-growth inhibition). Investors must await more granularity to gauge translational potential. Still, the use of Regulation FD suggests management’s confidence in the data’s market relevance. Near-term impact is sentiment driven; fundamental valuation change awaits in-vivo or clinical results.

Portfolio Manager

TL;DR: Sentiment boost, but no hard numbers — monitor for follow-up studies.

The filing discloses a potentially value-accretive event with no dilutive or financial downside. Because the information is furnished, liability is limited, yet the market often reacts to positive oncology headlines. I view the news as impactful for short-term trading but not sufficient for long-term position sizing until clinical validation emerges. Liquidity considerations: ordinary shares (SLXN) and warrants (SLXNW) both listed on Nasdaq, which could see volume spikes.

false000202241600-0000000972NASDAQNASDAQ00020224162025-07-092025-07-090002022416slxn:WarrantsExercisableForOrdinarySharesAtAnExercisePriceOf1150PerShareMember2025-07-092025-07-090002022416slxn:OrdinarySharesParValue00001PerShareMember2025-07-092025-07-09

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): July 9, 2025

Silexion Therapeutics Corp
(Exact name of registrant as specified in its charter)

Cayman Islands		001-42253		N/A
(State or other jurisdiction		(Commission File Number)		(I.R.S. Employer
of incorporation)				Identification No.)

12 Abba Hillel Road Ramat-Gan, Israel		5250606
(Address of principal executive offices)		(Zip Code)

+972-3-7564999

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary Shares, par value $0.0009 per share		SLXN		The Nasdaq Stock Market LLC
Warrants exercisable for Ordinary Shares at an exercise price of $103.50 per share		SLXNW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On July 9, 2025, Silexion Therapeutics Corp issued a press release entitled “Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines.” A copy of the press release is furnished with this Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

The information in Item 7.01 of this Form 8-K, including the information in the press release furnished pursuant to this Item 7.01 of Form 8-K, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Form 8-K, including the information in the press release, shall not be deemed to be incorporated by reference in the filings of the registrant under the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits 

(d) Exhibits

99.1		Press Release dated July 9, 2025
104		Cover Page Interactive Data File (formatted in Inline XBRL)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SILEXION THERAPEUTICS CORP
Date: July 9, 2025	/s/ Ilan Hadar
	Name:	Ilan Hadar
	Title:	Chief Executive Officer

FAQ

What did Silexion Therapeutics (SLXN) announce on July 9 2025?

The company furnished a press release reporting positive preclinical results for its lung-cancer candidate SIL204.

Which SEC form did SLXN file for this disclosure?

Silexion used a Form 8-K under Item 7.01 (Regulation FD).

Does the 8-K include financial figures or guidance?

No. The filing contains no financial data, earnings, or guidance; it only references the press release.

Are the disclosed results considered legally 'filed' with the SEC?

No. The information is furnished, not filed, so it is not subject to Section 18 liability or automatic incorporation into other filings.

Where can investors find detailed study data on SIL204?

Detailed data are contained in Exhibit 99.1 (the press release) attached to the 8-K.